BTIG Research Issues Positive Forecast for Glaukos (NYSE:GKOS) Stock Price

Key Points

• BTIG Research raised Glaukos’ price target from $205 to $234 and maintained a “buy” rating, implying roughly 29% upside from the reported share price.
• Glaukos reported a strong quarter, with revenue up 58% year over year to $211 million and adjusted EPS of $0.47, far exceeding analyst expectations for a loss.
• Despite a “Moderate Buy” analyst consensus and increased institutional ownership, insider selling and elevated valuation metrics remain potential risks for investors.

Glaukos (NYSE:GKOS - Get Free Report) had its target price upped by research analysts at BTIG Research from $205.00 to $234.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. BTIG Research's price target indicates a potential upside of 28.95% from the stock's current price.

Other equities analysts have also recently issued research reports about the stock. Wells Fargo & Company boosted their price target on shares of Glaukos from $138.00 to $178.00 and gave the company an "overweight" rating in a research report on Thursday, July 30th. Mizuho set a $225.00 target price on Glaukos in a report on Thursday. Citigroup lifted their price objective on Glaukos from $175.00 to $188.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Glaukos in a report on Thursday, October 15th. Finally, Truist Financial set a $255.00 price objective on shares of Glaukos in a research note on Thursday. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $194.93.

Glaukos Stock Up 0.2%

GKOS stock opened at $181.47 on Thursday. The company has a current ratio of 5.04, a quick ratio of 4.46 and a debt-to-equity ratio of 0.10. The company's 50 day moving average is $171.24 and its 200 day moving average is $139.87. Glaukos has a 1-year low of $76.88 and a 1-year high of $191.62. The stock has a market cap of $10.70 billion, a price-to-earnings ratio of -55.84 and a beta of 0.69.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to analysts' expectations of $168.04 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The company's revenue for the quarter was up 58.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.16) EPS. Sell-side analysts predict that Glaukos will post -0.32 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Leana Wen sold 525 shares of Glaukos stock in a transaction on Friday, July 31st. The stock was sold at an average price of $167.63, for a total transaction of $88,005.75. Following the transaction, the director owned 21,092 shares in the company, valued at approximately $3,535,651.96. The trade was a 2.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Alex Thurman sold 20,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total value of $3,602,600.00. Following the transaction, the chief financial officer owned 43,906 shares in the company, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,025 shares of company stock worth $14,950,006 in the last quarter. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Glaukos

Several institutional investors and hedge funds have recently made changes to their positions in the company. Sumitomo Mitsui Trust Group Inc. acquired a new stake in Glaukos in the third quarter valued at $1,248,000. Vise Technologies Inc. bought a new stake in shares of Glaukos during the 3rd quarter worth $668,000. State of Wyoming increased its holdings in Glaukos by 6.8% in the 3rd quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier's stock worth $169,000 after purchasing an additional 66 shares in the last quarter. Choreo LLC boosted its holdings in Glaukos by 4.0% in the third quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier's stock valued at $582,000 after acquiring an additional 136 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its stake in Glaukos by 35.6% during the third quarter. Fifth Third Wealth Advisors LLC now owns 2,172 shares of the medical instruments supplier's stock worth $357,000 after acquiring an additional 570 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record revenue beat expectations: Third-quarter revenue increased approximately 58% year over year to $211.0 million, exceeding the $168.0 million consensus estimate. Gross profit rose to $179.9 million. Glaukos Corporation Reports Third-Quarter Earnings
• Positive Sentiment: Profitability materially outperformed forecasts: Glaukos reported adjusted earnings of $0.47 per share, compared with analysts’ expected loss of approximately $0.10–$0.12 per share and a year-ago loss of $0.16. GAAP net income attributable to common shareholders was $2.0 million, or $0.03 per diluted share, marking a return to profitability. Glaukos Q3 Earnings and Revenue Results
• Positive Sentiment: Full-year guidance was sharply increased: Management raised 2026 net-sales guidance to $775 million–$785 million from $680 million–$700 million. It also introduced a preliminary 2027 sales target of approximately $1 billion, signaling confidence in sustained demand and product adoption. Glaukos Raises Sales Outlook
• Positive Sentiment: Cash generation remained solid: Operating activities generated $14.8 million, while Glaukos ended the quarter with $162.3 million in cash and cash equivalents and modest capital spending of $2.7 million.
• Neutral Sentiment: Investor expectations are elevated: The stock is near its 52-week high, while the reported P/E remains negative and the company continues to post negative trailing profitability metrics. Continued execution will be necessary to support the higher valuation.
• Negative Sentiment: Insider selling is a potential overhang: Company insiders reported 32 open-market sales and no purchases during the past six months. In addition, the median analyst price target cited in the provided reports was $165, below the current share-price range.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.